Some seven months after acquiring Canada’s Fusion Pharmaceuticals, AstraZeneca is expanding its footprint in the country with a fresh investment of C$820m ($570m).
AstraZeneca Sees Canada As Land Of Opportunity With $570m Investment
CEO Pascal Soriot said the deal, which will create more than 700 new jobs, reflected “our strong belief in Canada’s potential as a global hub for life sciences innovation, and the value of public-private collaboration.”
